focus -WSS

focus

author：Wikipedia 2025-09-03 11:52:39 - browse：638

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： A disappointing year of Humira biosimilars

hotspot

focus

WSS

CDC overhauls leadership of center that led response to Covid

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Novo acquires Inversago for up to $1 billion

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Vaccine advisory panel ACIP left half staffed by HHS

explore

focus

leisure time

Peter Hotez and the public health issue of online harassment

Kim Kardashian sparks debate on benefits of full

Medical leaders decry Supreme Court decision on affirmative action

Medicare threatens to cut off funding for HCA's Mission hospital

As demand for Covid shots wanes, Moderna seeks its next success

Biden report: The neurospychology of memory and aging

23andMe had bad news about my health. I wish a person had delivered it

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

What does generative AI mean for health care? We asked experts

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

explore

CDC overhauls leadership of center that led response to Covid

Newly revealed memo details efforts to keep Trump in power following election loss

The perfect storm of weather conditions that led to the devastating wildfires in Maui

The history of OxyContin, told through Purdue Pharma documents

Listen: Your guide to Wegovy's blockbuster heart study

Readout LOUD podcast: How biotech is using artificial intelligence

hotspot

focus

focus

entertainment